Prognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas: 8 years' clinical experience

Sadeleştirilmiş öğe sayfası
dc.contributor.authorMeseci, Elif
dc.contributor.authorNaki, Mehmet Murat
dc.date.accessioned2023-02-21T12:32:38Z
dc.date.available2023-02-21T12:32:38Z
dc.date.issued2019-01-01
dc.description.abstractObjective: To determine the clinical and pathologic characteristics, prognostic factors, surgical practice, adjuvant therapies, and survival outcomes of patients with uterine sarcoma diagnosed and treated in our institution. Material and Methods: Patients diagnosed and treated for uterine sarcomas at our institution from 2009 to 2017 were retrospectively evaluated. All histologic slides from the specimens underwent a thorough pathologic review by a gynecologic pathologist. The following variables were assessed: age, family history of cancer, smoking status, age of menarche, parity, age at first delivery, related symptoms, clinical staging, histologic type, treatment received, disease-free period, and the time and site of recurrence, as well as treatment of the latter and overall survival. Results: Ten patients were diagnosed as having leiomyosarcoma, a further 10 patients had malignant mixed mullerian tumors, and five had endometrial stromal sarcoma
dc.description.abstractthe remaining nine patients had other tumors. At the end of our study, 12 (35.3\%) patients were alive and in remission, four (11.8\%) were alive with disease, 10 (29.4\%) were lost to follow-up, and eight (23.5\%) had died. The mean survival time was 80.92 months, and the 2-year survival rate was 75.6\%. We found that survival was significantly shorter in the presence of lymph node involvement, residual tumor, and recurrence. Conclusion: This study serves to inform physicians about the outcome of various uterine sarcomas that were diagnosed and managed at our center. We found that 35.3\% of our patients were alive and in remission, 11.8\% were alive with disease, 29.4\% were lost to follow-up, and 23.5\% of patients died.
dc.description.issue3
dc.description.issueSEP
dc.description.pages154-164
dc.description.volume20
dc.identifier.doi10.4274/jtgga.galenos.2019.2019.0061
dc.identifier.urihttps://hdl.handle.net/11443/1193
dc.identifier.urihttp://dx.doi.org/10.4274/jtgga.galenos.2019.2019.0061
dc.identifier.wosWOS:000483978800006
dc.publisherGALENOS YAYINCILIK
dc.relation.ispartofJOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION
dc.subjectCarcinosarcoma
dc.subjectleiomyosarcoma
dc.subjectprognosis
dc.subjectsarcoma
dc.subjectsurvival
dc.titlePrognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas: 8 years' clinical experience
dc.typeArticle
Dosyalar
Orijinal seri
Şimdi gösteriliyor 1 - 1 / 1
thumbnail.default.alt
Ad:
Prognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas 8 years' clinical experience.pdf
Boyut:
542.71 KB
Format:
Adobe Portable Document Format
Açıklama
İndir
Koleksiyonlar
WOS